Global Drug
Abuse Treatment Market, by Abuse Type (Alcohol Dependence, Tobacco/Nicotine
Addiction, and Opioid Addiction), by Drug Type (Disulfiram, Acamprosate,
Naltrexone, Methadone, Buprenorphine, Nicotine Addiction Treatment ((Nicotine
Replacement Treatment (Nicotine Patch, Nicotine Gum, Nicotine Lozenge, Nicotine
Spray, and Nicotine Inhaler)) ((Non-Nicotine Medication, (Bupropion, and Varenicline)),
and Others), by Distribution Channel (Hospital, Retail Pharmacy, and Online
Pharmacy) and by Region (North America, Latin America, Europe, Asia Pacific,
the Middle East, and Africa) was valued at US$ 13.4 Bn in 2017, and is
projected to exhibit a CAGR of 7.8% over the forecast period (2018 – 2026).
Increasing launches of novel
drugs for treatment of drug abuse in market is expected to drive the global
drug abuse treatment market growth in near future. For instance, in 2015, Mylan
N.V. launched its new drugs Disulfiram Tablets USP, 250 mg and 500 mg in the
U.S. market, drugs Disulfiram Tablets USP is a generic version of Odyssey
Pharmaceutical's Antabuse. In 2017, Glenmark Pharmaceuticals launched its new
nicotine replacement therapy namely Kwitz in India. Kwitz is a nicotine gum and
is available in two variants Kwitz 2 mg and Kwitz 4 mg. Kwitz 2 mg is for the
smokers having less than 20 cigarettes per day and Kwitz 4 mg is for those who
smoke more than 20 cigarettes per day. In April 2018, Lil' Drug Store Products
Inc. launched its Nicotac brand nicotine gum in market. Lil' Drug Store
Products Inc. has launched its Nicotac in two nicotine strengths (2 mg and 4 mg
nicotine polarcrilex). In 2017, Cipla Health, an arm of Cipla Limited launched
a new Nicotex Nicotine Patches. Nicotex Nicotine Patches are skin/transdermal
patches, which helps to quit smoking in 12 months. Company has launched its
patches in 3 strengths 21 mg, 14 mg, and 7 mg. 21 mg patch is for one who smoke
more than 20 cigarette a day, 14 mg is for those who smoke less that 20
cigarette a day
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2011
Browse 23 Market Data Tables and
26 Figures spread through 180 Pages and in-depth TOC on Drug Abuse Treatment
Market By Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, and
Opioid Addiction), By Drug Type (Disulfiram, Acamprosate, Naltrexone,
Methadone, Buprenorphine, Nicotine Addiction Treatment ((Nicotine Replacement
Treatment (Nicotine Patch, Nicotine Gum, Nicotine Lozenge, Nicotine Spray,
Nicotine Inhaler)) ((Non-Nicotine Medication, (Bupropion, and Varenicline)),
and Others), By Distribution Channel (Hospital, Retail Pharmacy, and Online
Pharmacy) and Region (North America,
Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global
Forecast to 2026
Furthermore, increasing
prevalence of drug abuse and dependence in key regions are expected to increase
the demand for its treatment and management drugs in near future. For instance,
according to the Substance Abuse and Mental Health Services Administration
(SAMHSA), around 830,000 people in the U.S. used heroin in 2015, which is more
than double the number from 2002. Such increasing rates of drugs abuse are
expected to fuel growth of the global drug abuse treatment market in near
future.
Key Takeaways of the Drug Abuse
Treatment Market:
The global drug abuse treatment
market is expected to exhibit a CAGR of 7.8% over the forecast period (2018 –
2026), owing to frequent product launches, approval and robust pipeline of
novel biopharmaceutical products
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/drug-abuse-treatment-market-2011
North America held the dominant
position in the global drug abuse treatment market and is expected to retain
its dominance over the forecast period (2018 – 2026). This is due to the high
rates of drug abuse in region, which are expected to increase demand for its
treatment drugs over the forecast period. For instance, according to the data
published by National Institute of Alcohol abuse and Alcoholism in 2015, around
15.1 million adults ages 18 and older (6.2 percent of this age group) are
suffering from Alcohol Use Disorder. This includes 9.8 million men (8.4 percent
of men in this age group) and 5.3 million women
Asia Pacific is expected to
witness significant growth over the forecast period due to increasing launches
of novel drugs by key players in the region. For instance, in 2017, Glenmark
Pharmaceuticals launched a new Kwitz is a nicotine gum in India.
Major players operating in the
drug abuse treatment market include Cipla Limited, Glenmark Pharmaceuticals,
Pfizer Inc., Mylan N.V., Odyssey Pharmaceuticals Inc., Lil' Drug Store Products
Inc., Indivior Plc., Dr. Reddy's Laboratories, Teva Pharmaceutical Industries
Ltd., and British American Tobacco Plc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2011
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment